Corient Private Wealth LP Has $577.64 Million Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Corient Private Wealth reduced its Johnson & Johnson position by 14.7% in the second quarter, selling 392,496 shares. It still held 2.27 million shares worth approximately $577.6 million, representing 0.8% of its portfolio.
• Johnson & Johnson reported quarterly revenue of $25.31 billion and adjusted EPS of $2.90, exceeding analyst expectations, while revenue increased 6.6% year over year. The company also maintains a $1.34 quarterly dividend, yielding about 2.0% annually.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $274.13. Investors are watching potential value creation from a DePuy Synthes divestiture and strong Rybrevant cancer results, alongside the setback for the JNJ-5120 depression treatment.

Corient Private Wealth LP lowered its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,274,445 shares of the company's stock after selling 392,496 shares during the quarter. Johnson & Johnson accounts for about 0.8% of Corient Private Wealth LP's holdings, making the stock its 19th largest position. Corient Private Wealth LP owned 0.09% of Johnson & Johnson worth $577,641,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Tucker Asset Management LLC raised its stake in shares of Johnson & Johnson by 173.4% in the second quarter. Tucker Asset Management LLC now owns 5,011 shares of the company's stock valued at $1,273,000 after purchasing an additional 3,178 shares in the last quarter. Principia Wealth Advisory LLC increased its holdings in Johnson & Johnson by 208.7% in the 2nd quarter. Principia Wealth Advisory LLC now owns 815 shares of the company's stock valued at $207,000 after buying an additional 551 shares during the period. Brown Financial Advisors raised its stake in shares of Johnson & Johnson by 10.6% in the 2nd quarter. Brown Financial Advisors now owns 7,216 shares of the company's stock valued at $1,833,000 after buying an additional 694 shares in the last quarter. Advus Financial Partners LLC lifted its holdings in shares of Johnson & Johnson by 4.5% during the 2nd quarter. Advus Financial Partners LLC now owns 7,402 shares of the company's stock worth $1,880,000 after acquiring an additional 317 shares during the period. Finally, Groupe la Francaise lifted its holdings in shares of Johnson & Johnson by 991.4% during the 2nd quarter. Groupe la Francaise now owns 198,681 shares of the company's stock worth $50,466,000 after acquiring an additional 180,477 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Up 0.2%

NYSE JNJ opened at $266.94 on Wednesday. The stock's 50 day simple moving average is $263.17 and its 200 day simple moving average is $246.23. Johnson & Johnson has a one year low of $173.33 and a one year high of $281.07. The firm has a market cap of $643.29 billion, a PE ratio of 30.93, a price-to-earnings-growth ratio of 2.54 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business's revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is presently 62.11%.

Insider Activity at Johnson & Johnson

In other news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 87,569 shares of company stock valued at $23,064,544 over the last three months. 0.16% of the stock is owned by company insiders.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Potential $20 billion DePuy Synthes sale could unlock value. Apollo Global Management is reportedly in talks to acquire J&J’s DePuy Synthes orthopedics business, which generated approximately $9.3 billion in 2025 revenue. A sale or spinoff could sharpen J&J’s focus and return capital to shareholders. Apollo and J&J Face a High-Stakes Orthopedics Deal
• Positive Sentiment: Rybrevant delivers strong lung-cancer results. J&J reported that Rybrevant plus chemotherapy produced a 34.3-month median overall survival in EGFR exon 20 insertion-positive non-small-cell lung cancer, described as the longest reported result for this population. Separate data also showed fewer treatment-related events with the Rybrevant Faspro and Lazcluze combination, supporting the oncology pipeline and potential commercial momentum. Johnson & Johnson Says Lung Cancer Drug Shows Reduced Side Effects and Longer Patient Survival
• Positive Sentiment: Analyst and defensive-investment support remain favorable. TD Cowen maintained a Buy rating with a $300 price target, citing oncology momentum and the possible DePuy Synthes transaction. J&J is also being highlighted as a reliable dividend and defensive healthcare holding, which may attract investors during market volatility. J&J: Oncology Momentum and Potential $20B DePuy Synthes Divestiture Support Buy Rating
• Neutral Sentiment: Investors are monitoring strategic and fundamental developments. Attention is focused on J&J’s ability to achieve double-digit growth while Stelara faces biosimilar competition. Recent institutional activity has been mixed, while reported insider transactions consisted entirely of sales over the past six months.
• Negative Sentiment: Clinical setback hits a partnered depression treatment. JNJ-5120, also known as PIPE-307, failed to meet the primary endpoint in the Phase 2 MOONLIGHT-1 trial for major depressive disorder. J&J is reviewing additional data, but the failure reduces confidence in this portion of its drug-development pipeline. Contineum, J&J's Depression Drug Fails to Meet Mid-Stage Trial Goal

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JNJ. Guggenheim increased their price target on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a research report on Thursday, August 6th. Royal Bank Of Canada upped their price objective on Johnson & Johnson from $265.00 to $287.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. UBS Group started coverage on Johnson & Johnson in a report on Wednesday, September 2nd. They issued a "buy" rating and a $320.00 target price for the company. Johnson Rice restated a "buy" rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Finally, Raymond James Financial set a $280.00 price target on Johnson & Johnson in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $274.13.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.